Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2008-10-27
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00316511
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-10-27
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00231049
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT00126178
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00098085
Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
Phase 2
Terminated
- Conditions
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00082459
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00081809
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢
Phase 2
Terminated
- Conditions
- First Posted Date
- 2003-04-15
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00058747
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT00039000
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-04-15
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 650
- Registration Number
- NCT00033904
© Copyright 2024. All Rights Reserved by MedPath